3rd email to Andy Robinson, Managing Director, Publishing at CABI. This Petition Update follows the previous two: 

Is CABI promoting a false public health narrative? 

Is CABI promoting a false public health narrative? (Part 2)

---------- Original Message ----------
From: CARL TUTTLE <runagain@comcast.net>
To: Andy Robinson <A.Robinson@cabi.org>
Date: 09/06/2025 8:47 AM EDT
Subject: RE: Is CABI promoting a false public health narrative?
 
 
CABI Digital Library
 
Lyme Disease: An Evidence-based Approach   pp. 74-88
Borrelia: Interactions with the Host Immune System
Authors: Kirk Sperber , Raymond J. Dattwyler  
 
Abstract
 
"Borrelia burgdorferi (Bb) has a complex interaction with its host, allowing it to evade both humoral and cellular immunity."
 
 
Dr. Robinson,
 
 
Guideline signatory Raymond Dattwyler endorses the categorical assertion that chronic Lyme disease does not exist yet his patent for novel chimeric nucleic acids and protein antigens which could serve as a basis for a vaccine or for improved immunodiagnostic reagents for Lyme disease, issuing almost contemporaneously with the 2006 IDSA Lyme Disease Guidelines seems to say exactly the opposite: 

“Currently, Lyme Disease is treated with a range of antibiotics, e.g. tetracycline, penicillin and cephalosporins. However, such treatment is not always successful in clearing the infection. Treatment is often delayed due to improper diagnosis with the deleterious effect that the infection proceeds to a chronic condition, where treatment with antibiotics is often not useful. One of the factors contributing to delayed treatment is the lack of effective diagnostic tools.” (Dattwyler, et.al. United States Patent 7,179,448)
 
Please take a moment if you will to review the following inquiry addressed to doctor Dattwyler who has set the stage for long-term treatment denial. It should be noted that there was no response.
 
 
Carl Tuttle
 
 
 
---------- Original Message ----------
From: CARL TUTTLE <runagain@comcast.net> 
To: Raymond_Dattwyler@nymc.edu 
Cc: npjvaccines@nature.com, abarrett@utmb.edu, R.W.Titball@exeter.ac.uk, mgomesso@uthsc.edu
Date: 01/06/2023 2:46 PM EST
Subject: The year that shaped the outcome of the OspA vaccine for human Lyme disease
 
 
npj Vaccines Jan 2022
 
The year that shaped the outcome of the OspA vaccine for human Lyme disease
https://www.nature.com/articles/s41541-022-00429-5
Raymond J. Dattwyler & Maria Gomes-Solecki
 
 
Department of Microbiology and Immunology
New York Medical College
Valhalla, NY
Raymond J. Dattwyler, Corresponding Author
 
Dear Dr. Dattwyler,
 
I read your manuscript with great interest as you call attention to a treatment-resistant Lyme arthritis with “no evidence of DNA” found in the joints of patients after antibiotic treatment.
 
For some strange reason however, I could not find the following 1995 publication within your paper identifying treatment-resistant neuroborreliosis:
 
 
European Neurology 1995
 
Seronegative Chronic Relapsing Neuroborreliosis
https://www.karger.com/Article/Abstract/117104
Lawrence C., Lipton R.B., Lowy F.D., Coyle P.K.d
 
Abstract
 
We report an unusual patient with evidence of Borrelia burgdorferi infection who experienced repeated neurologic relapses despite aggressive antibiotic therapy. Each course of therapy was associated with a Jarisch-Herxheimer-like reaction. Although the patient never had detectable free antibodies to B. burgdorferi in serum or spinal fluid, the CSF was positive on multiple occasions for complexed anti-B. burgdorferi antibodies, B. burgdorferi nucleic acids and free antigen.
 
 
In fact, Dr. Dattwyler there seems to be a great deal of “treatment-resistant” evidence published in multiple journals over the past three decades:
 
Peer Reviewed Evidence of Persistence of Lyme Disease Spirochete Borrelia burgdorferi and Tick-Borne Diseases (700 References)
https://www.dropbox.com/s/n09sk90eo6xz7ua/700%20articles%20LYME%20EvidenceofPersistence-V2.pdf?dl=0
 
 
So that brings me to the reason for this email...
 
Question:
 
Does a chronic relapsing seronegative disease fit the vaccine model? If not, would that, in and of itself, be the hidden reason for denying chronic (treatment-resistant) Lyme disease for almost three decades?  In other words, patent royalties and pharmaceutical profits over lifesaving care?
 
 
A response to this inquiry is requested.
 
 
 
Carl Tuttle
Hudson, NH
 
 
Cc: Alan D.T. Barrett, PhD Editor-in-Chief
Rick Titball, PhD, DSc, Deputy Editor
 
 
Letter to the Editor of the BMJ published June 2020
https://www.bmj.com/content/369/bmj.m1041/rr-1